ILD Learning Center Content Directory

Effects of respiratory muscle training in patients with interstitial lung diseases: Systematic review

December 2025

News

CONCLUSION: Considering the small number of articles included in this systematic review, IMT programs lasting ≥6 weeks appear beneficial and safe for improving respiratory muscle strength, dyspnea, and functional exercise capacity. However, more rigorous studies are needed to confirm these benefits.

Erector spinae muscle thickness predicts mortality in patients with pulmonary diseases

December 2025

News

CONCLUSION: ESM(T) is a useful and easy marker for predicting 1-year mortality and impaired ADL status in patients with pulmonary diseases.

Synthesis of a hemicyanine-based near-infrared fluorescent probe for the diagnosis of pulmonary fibrosis and acute lung injury

December 2025

News

BACKGROUND: Pulmonary fibrosis (PF) and acute lung injury (ALI) are severe and often fatal pulmonary conditions with high morbidity and limited treatment options, characterized by progressive interstitial scarring or acute diffuse alveolar damage, respectively. Mitochondrial dysfunction is increasingly implicated in their pathogenesis, and LACTB (Lactamase beta), a mitochondrial serine protease, is a potential regulator of these. However, current diagnostics cannot capture early molecular or...

Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases

December 2025

News

CONCLUSIONS: GAP stage and BMI can be useful for predicting prognosis and future nintedanib discontinuation in patients with IPF and PF-ILDs. Nintedanib treatment may be considered in patients with IPF and PF-ILDs in an earlier stage of the disease.

Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis

December 2025

News

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease in which endothelial cell senescence (ECS) plays a key role. By integrating two GEO transcriptome datasets (145 IPF patients and 84 controls) and applying LASSO, SVM-RFE, and Boruta algorithms, four key ECS-related genes (ECSRGs), MYCT1, PLEKHA1, PCDH12, and PLXND1, were identified. MYCT1 and PLEKHA1 were downregulated by about 26% and 75%, while PCDH12 and PLXND1 were upregulated by 2.4- and 1.9-fold (p < 0.0001)....

Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan

December 2025

News

CONCLUSION: The incidence of ILD with T-DXd in the real-world setting was similar to that observed in clinical trials, indicating no new ILD-related safety signals. Further investigation of the identified factors may offer insights into ILD incidence in high-risk populations.

Uncovering mirnomes of patients with interstitial lung diseases and an underlying autoimmune process

December 2025

News

Interstitial lung disease (ILD) is a major manifestation of systemic autoimmune rheumatic diseases (SARD). Unmet needs in this population are the early identification of patients at risk of functional deterioration and tailoring therapies on a pathophysiological basis. The study of microRNA is being applied to trace pathogenetic mechanisms and as predictive tool in complex diseases. We have performed bulk small-RNA sequencing in sera from 24 patients with SARD-associated ILD and 5 healthy...

A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol

December 2025

News

BACKGROUND: Interstitial lung disease (ILD) has a profound impact upon health-related quality of life (HRQoL) and mortality. Patients with ILD have identified their desire for tools to improve self-management. This study compares the clinical efficacy and cost-effectiveness of delivering an ILD-specific self-management package through a mobile health smartphone application (the REBUILD app), with standard care. It also evaluates the barriers and facilitators to adoption of the intervention in...

Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer

December 2025

News

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a markedly poor prognosis, imposing a heavy burden on society and being prone to various comorbidities, with lung cancer (LC) being one of the most common. Although IPF and LC have not been characterized as overlapping syndromes, a high incidence and unfavorable prognosis have been revealed for IPF combined with LC (IPF-LC). Therefore, the clinical characteristics of patients with IPF-LC vs. those with IPF alone were...

Biotechnology-based therapies for mitigation of pulmonary fibrosis: an update

December 2025

News

Pulmonary fibrosis (PF) is a chronic interstitial lung disease that causes inflammation and scarring around the lung alveoli. This scarring is called fibrosis and leads to breathing difficulties in patients. The treatment for PF is currently limited to two drugs: nintedanib and pirfenidone. Their use is restricted owing to poor bioavailability and a few contraindications. Biotechnological advancements are leading to the investigation of targeted systems aimed at reversing alveolar damage and...